Free Trial
NASDAQ:FEMY

Femasys 5/11/2023 Earnings Report

Femasys logo
$1.16 -0.07 (-5.69%)
Closing price 04/28/2025 04:00 PM Eastern
Extended Trading
$1.20 +0.04 (+3.36%)
As of 04/28/2025 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Femasys EPS Results

Actual EPS
-$0.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
$0.29 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Femasys' next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules.

Conference Call Resources

Femasys Earnings Headlines

Femasys (NASDAQ:FEMY) Stock Price Down 3.2% - Here's Why
Femasys reports FY24 EPS (85c), consensus (81c)
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Femasys enters partnership with CNY Fertility
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY), a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

View Femasys Profile

More Earnings Resources from MarketBeat